MedTrace Logo

A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562

NCT04941989 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-02-20

No results posted yet for this study

Summary

Phase 1, randomised, double-blind, first in human, two part, single centre, placebo controlled, single and multiple ascending dose trial in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of HTL0022562.

Conditions

  • Healthy

Interventions

DRUG

HTL0022562

HTL0022562

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Nxera Pharma UK Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-25
Primary Completion
2021-11-19
Completion
2021-11-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04941989 on ClinicalTrials.gov